Sign InEli Lilly's Obesity Drug Boosts Market Confidence, Analysts Recommend Buying
Summary
Eli Lilly and Company's stock is predicted to increase in the short term, driven by positive news about their obesity drug and the market reaction to their rival's trial outcome, making it a Buy with potential high price volatility.
Fundamental Analysis
Eli Lilly and Company (LLY) closed at $605.28 on October 11, 2023, up 4.48% from the prior trading day. The bullish market trend on this particular day is possibly driven by positive news relating to the company's obesity drug, tirzepatide, pending FDA approval and its potential in the projected $150 billion GLP-1 therapy market in the US by 2030. Increases in employer coverage are further fueling optimism about Eli Lilly's future growth.
The firm's growth opportunities are further supported by the fact that its main rival, Novo Nordisk, had stopped a trial due to a positive outcome in the treatment of kidney failure in diabetes. This development boosted Eli Lilly's share price by 2.6% in pre-market trading.
Earnings per share (EPS) currently stand at $7.2, supporting the company's profitability. The price-to-earnings ratio (P/E) of 84.07 suggests investor's high expectations, reflecting a pricing premium due to anticipated future earnings growth.
An upcoming earnings announcement on November 2, 2023, will provide a more reliable view of the company's financial status. Additionally, the Discounted Cash Flow (DCF) that indicates the potential value of an investment stands at $607.57, suggesting the stock is slightly undervalued.
The market cap of Eli Lilly is approximately $574.59 billion, highlighting the company's significant size and influence within the market. Meanwhile, with 949.29 million shares outstanding, the stock's liquidity is also commendable.
Technical Analysis
Technical indicators suggest elevated stock price volatility. The 14-day Relative Strength Index (RSI14), a momentum oscillator, stands at 75, indicating the stock is being overbought.
The stock is currently trading above its 50-day moving average (MA) of $544.81 and well above its 200-day MA of $427.12, pointing to a strong upward trend. However, the negative Moving Average Convergence Divergence (MACD, 3-month) of -12.38 suggests a downward pressure on the stock.
There is a potential upside for Eli Lilly with a consensus target price of $396 and on the higher side $673. However, downside risk exists with a target low of $236.
The price range over the last trading day was from $585.01 to $608.79, indicating significant market volatility. The stock’s stop loss level is determined at $584.10. The company has a robust support level at $575.66.
Stock Prediction
Given the fundamental strength of Eli Lilly and the current upward trend, it's predicted that the stock will increase in the short term, potentially trading between the support level of $575.66 and the previous high of $608.79 during the next trading day, October 12, 2023.
Over the upcoming week, the stock may aim to surpass its past year high of $608.79, though the high P/E ratio, along with overbought RSI indications, leave some risk of a price adjustment.
Final Evaluation
Despite some bearish technical signals, Eli Lilly's fundamentals, particularly the promising news about tirzepatide and the positive market reaction to Novo Nordisk's halted trial, still make the stock attractive. The consensus on the stock among analysts is a 'buy.'
Considering all these factors, Eli Lilly and Company's stock is categorized as a Buy at this point. Potential investors can consider buying the stock but do be aware of the probable high price volatility in the short term. Top-level corporate news (like FDA approvals), quarterly earnings, and shifts in the industry scenario surrounding the diabetes treatment landscape should be keenly monitored.
